Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation.

Bosch-Vilaseca A, García-Cadenas I, Roldán E, Novelli S, Barba P, Esquirol A, Valcárcel D, Martino R, Sierra J.

Eur J Haematol. 2018 Jun 29. doi: 10.1111/ejh.13132. [Epub ahead of print]

PMID:
29956377
2.

The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.

Xicoy B, Triguero A, Such E, García O, Jiménez MJ, Arnán M, Bernal T, Diaz-Beya M, Valcárcel D, Pedro C, Ramos F, Amigo ML, Collado R, Palomo L, Ardanaz MT, Cedena MT, Grau J, Zamora L, Sanz G.

Leuk Res. 2018 May 9;70:34-36. doi: 10.1016/j.leukres.2018.05.003. [Epub ahead of print] No abstract available.

PMID:
29775844
3.

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.

Cabezón M, Bargay J, Xicoy B, García O, Borrás J, Tormo M, Marcé S, Pedro C, Valcárcel D, Jiménez MJ, Guàrdia R, Palomo L, Brunet S, Vall-Llovera F, Garcia A, Feliu E, Zamora L; CETLAM Group.

Oncotarget. 2018 Apr 10;9(27):19342-19355. doi: 10.18632/oncotarget.25046. eCollection 2018 Apr 10.

4.

Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.

Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellví J, Saumell S, Bobillo S, Bosch F, Valcárcel D.

Ann Hematol. 2018 Aug;97(8):1349-1356. doi: 10.1007/s00277-018-3302-0. Epub 2018 Mar 23.

PMID:
29572561
5.

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.

Ortí G, Sanz J, García-Cadenas I, Sánchez-Ortega I, Alonso L, Jiménez MJ, Sisinni L, Azqueta C, Salamero O, Badell I, Ferra C, de Heredia CD, Parody R, Sanz MA, Sierra J, Piñana JL, Querol S, Valcárcel D.

Exp Hematol. 2018 Jun;62:24-32. doi: 10.1016/j.exphem.2018.03.002. Epub 2018 Mar 8.

PMID:
29526774
6.

Registered Replication Report: Dijksterhuis and van Knippenberg (1998).

O'Donnell M, Nelson LD, Ackermann E, Aczel B, Akhtar A, Aldrovandi S, Alshaif N, Andringa R, Aveyard M, Babincak P, Balatekin N, Baldwin SA, Banik G, Baskin E, Bell R, Białobrzeska O, Birt AR, Boot WR, Braithwaite SR, Briggs JC, Buchner A, Budd D, Budzik K, Bullens L, Bulley RL, Cannon PR, Cantarero K, Cesario J, Chambers S, Chartier CR, Chekroun P, Chong C, Cleeremans A, Coary SP, Coulthard J, Cramwinckel FM, Denson TF, Díaz-Lago M, DiDonato TE, Drummond A, Eberlen J, Ebersbach T, Edlund JE, Finnigan KM, Fisher J, Frankowska N, García-Sánchez E, Golom FD, Graves AJ, Greenberg K, Hanioti M, Hansen HA, Harder JA, Harrell ER, Hartanto A, Inzlicht M, Johnson DJ, Karpinski A, Keller VN, Klein O, Koppel L, Krahmer E, Lantian A, Larson MJ, Légal JB, Lucas RE, Lynott D, Magaldino CM, Massar K, McBee MT, McLatchie N, Melia N, Mensink MC, Mieth L, Moore-Berg S, Neeser G, Newell BR, Noordewier MK, Ali Özdoğru A, Pantazi M, Parzuchowski M, Peters K, Philipp MC, Pollmann MMH, Rentzelas P, Rodríguez-Bailón R, Philipp Röer J, Ropovik I, Roque NA, Rueda C, Rutjens BT, Sackett K, Salamon J, Sánchez-Rodríguez Á, Saunders B, Schaafsma J, Schulte-Mecklenbeck M, Shanks DR, Sherman MF, Steele KM, Steffens NK, Sun J, Susa KJ, Szaszi B, Szollosi A, Tamayo RM, Tinghög G, Tong YY, Tweten C, Vadillo MA, Valcarcel D, Van der Linden N, van Elk M, van Harreveld F, Västfjäll D, Vazire S, Verduyn P, Williams MN, Willis GB, Wood SE, Yang C, Zerhouni O, Zheng R, Zrubka M.

Perspect Psychol Sci. 2018 Mar;13(2):268-294. doi: 10.1177/1745691618755704. Epub 2018 Feb 21.

PMID:
29463182
7.

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez-Malaver FJ, Valcárcel D, Solano C, López-Corral L, Sierra J, Perales MA.

Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2.

PMID:
29305194
8.

Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.

Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luño E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Díez-Campelo M, Ortega M, Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group.

Leuk Res. 2017 Dec;63:85-89. doi: 10.1016/j.leukres.2017.10.011. Epub 2017 Oct 28.

PMID:
29121539
9.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.

Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG.

Leukemia. 2017 Dec;31(12):2799-2806. doi: 10.1038/leu.2017.159. Epub 2017 May 26.

10.

A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.

Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, Barba P, Hernandez-Boluda JC, Esquirol A, Fox ML, Terol MJ, Queraltó JM, Vima J, Valcarcel D, Ferriols-Lisart R, Sierra J, Solano C, Martino R.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1177-1185. doi: 10.1016/j.bbmt.2017.03.035. Epub 2017 Apr 7.

11.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.

Biol Blood Marrow Transplant. 2017 Jun;23(6):971-979. doi: 10.1016/j.bbmt.2017.03.014. Epub 2017 Mar 10.

12.

Do Patients and Physicians Agree When They Assess Quality of Life?

Barata A, Martino R, Gich I, García-Cadenas I, Abella E, Barba P, Briones J, Brunet S, Esquirol A, García-Pallarols F, Garrido A, Granell M, Martinez J, Mensa I, Novelli S, Sánchez-González B, Valcárcel D, Sierra J.

Biol Blood Marrow Transplant. 2017 Jun;23(6):1005-1010. doi: 10.1016/j.bbmt.2017.03.015. Epub 2017 Mar 10.

13.

Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect.

Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D.

Exp Hematol. 2017 Apr;48:1-11. doi: 10.1016/j.exphem.2016.12.004. Epub 2016 Dec 24. Review.

PMID:
28027963
14.

Imported Disease Screening Prior to Chemotherapy and Bone Marrow Transplantation for Oncohematological Malignancies.

Sánchez-Montalvá A, Salvador F, Ruiz-Camps I, Barba P, Valcárcel D, Sulleiro E, Sanz-García E, Molina I.

Am J Trop Med Hyg. 2016 Dec 7;95(6):1463-1468. Epub 2016 Oct 17.

15.

Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin.

Castillo N, García-Cadenas I, Barba P, Canals C, Díaz-Heredia C, Martino R, Ferrà C, Badell I, Elorza I, Sierra J, Valcárcel D, Querol S.

Biol Blood Marrow Transplant. 2017 Mar;23(3):491-497. doi: 10.1016/j.bbmt.2016.11.014. Epub 2016 Nov 22.

16.

Excess mortality in the myelodysplastic syndromes.

Nomdedeu M, Pereira A, Ramos F, Valcárcel D, Costa D, Arnan M, Calvo X, Pomares H, Luño E, Díaz-Campelo M, Collado R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J, Tormo M, Cedena MT, Nomdedeu B, Sanz G; Spanish MDS Group.

Am J Hematol. 2017 Feb;92(2):149-154. doi: 10.1002/ajh.24606. Epub 2016 Dec 7.

17.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA.

Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7.

PMID:
27819684
18.

Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.

Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético).

Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. Epub 2016 Jun 29.

19.

Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis.

Montoro J, Robledo C, Zamora L, Valcárcel D, Ramos F.

Ann Hematol. 2017 Feb;96(2):317-318. doi: 10.1007/s00277-016-2849-x. Epub 2016 Oct 12. No abstract available.

PMID:
27730343
20.

Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease.

García-Cadenas I, Rivera I, Martino R, Esquirol A, Barba P, Novelli S, Orti G, Briones J, Brunet S, Valcarcel D, Sierra J.

Bone Marrow Transplant. 2017 Jan;52(1):107-113. doi: 10.1038/bmt.2016.225. Epub 2016 Sep 5.

PMID:
27595281
21.

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).

Montesinos P, Cabrero M, Valcárcel D, Rovira M, García-Marco JA, Loscertales J, Moreno C, Duarte R, Terol MJ, Villamor N, Abrisqueta P, Caballero D, Sanz J, Delgado J.

Bone Marrow Transplant. 2016 Oct;51(10):1404-1407. doi: 10.1038/bmt.2016.145. Epub 2016 May 23. No abstract available.

PMID:
27214073
22.
23.

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W.

J Clin Oncol. 2016 Jun 1;34(16):1864-71. doi: 10.1200/JCO.2015.65.0515. Epub 2016 Apr 4.

24.

Cord Blood Units with High CD3(+) Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation.

Castillo N, García-Cadenas I, Díaz-Heredia C, Martino R, Barba P, Ferrà C, Canals C, Elorza I, Olivé T, Badell I, Sierra J, Valcárcel D, Querol S.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1073-1079. doi: 10.1016/j.bbmt.2016.03.009. Epub 2016 Mar 30.

25.

[Bacteraemia and infection of the vascular catheter in the haematology patient: positioning and management based on the Delphi method].

Azanza-Perea JR, López-Jiménez J, Parody-Porras R, Salavert-Lletí M, Solano C, Valcárcel D, Vallejo-Llamas C, Vázquez-López L, Rivas-González P.

Rev Esp Quimioter. 2016 Feb;29(1):15-24. Epub 2016 Feb 15. Spanish.

26.

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Diez-Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, Andreu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy B, Ramos F, Bargay J, Gonzalez B, Brunet S, Muñoz JA, Gomez V, Bailén A, Sanchez J, Merchán B, del Cañizo C, Vallespí T; Grupo Español de Síndromes Mielodisplásicos (GESMD).

Lancet Haematol. 2015 Jun;2(6):e260-6. doi: 10.1016/S2352-3026(15)00067-8. Epub 2015 May 20.

PMID:
26688236
27.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.

Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferrà C, García-Noblejas A, Jimenez S, Sampol A, Yañez L, García-Gutiérrez V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF.

Biol Blood Marrow Transplant. 2016 Mar;22(3):584-8. doi: 10.1016/j.bbmt.2015.11.012. Epub 2015 Nov 26.

28.

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Eur J Haematol. 2016 Jul;97(1):33-8. doi: 10.1111/ejh.12679. Epub 2015 Oct 22.

PMID:
26341961
29.

Post-Thaw Viable CD45+ Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases.

Castillo N, García-Cadenas I, Barba P, Martino R, Azqueta C, Ferrà C, Canals C, Sierra J, Valcárcel D, Querol S.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2167-2172. doi: 10.1016/j.bbmt.2015.08.016. Epub 2015 Aug 28.

30.

Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.

Halter JP, Michael W, Schüpbach M, Mandel H, Casali C, Orchard K, Collin M, Valcarcel D, Rovelli A, Filosto M, Dotti MT, Marotta G, Pintos G, Barba P, Accarino A, Ferra C, Illa I, Beguin Y, Bakker JA, Boelens JJ, de Coo IF, Fay K, Sue CM, Nachbaur D, Zoller H, Sobreira C, Pinto Simoes B, Hammans SR, Savage D, Martí R, Chinnery PF, Elhasid R, Gratwohl A, Hirano M.

Brain. 2015 Oct;138(Pt 10):2847-58. doi: 10.1093/brain/awv226. Epub 2015 Aug 10.

31.

Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale.

Bonanad S, De la Rubia J, Gironella M, Pérez Persona E, González B, Fernández Lago C, Arnan M, Zudaire M, Hernández Rivas JA, Soler A, Marrero C, Olivier C, Altés A, Valcárcel D, Hernández MT, Oiartzabal I, Fernández Ordoño R, Arnao M, Esquerra A, Sarrá J, González-Barca E, González J, Calvo X, Nomdedeu M, García Guiñón A, Ramírez Payer A, Casado A, López S, Durán M, Marcos M, Cruz-Jentoft AJ; GAH Group.

J Geriatr Oncol. 2015 Sep;6(5):353-61. doi: 10.1016/j.jgo.2015.03.003. Epub 2015 Jun 29.

PMID:
26139300
32.

Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation.

Barba P, Martino R, Orti G, Esquirol A, Perez-Hoyos S, Sierra J, Valcárcel D.

Bone Marrow Transplant. 2015 Oct;50(10):1371-4. doi: 10.1038/bmt.2015.144. Epub 2015 Jun 22. No abstract available.

PMID:
26098954
33.

Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?

Saumell S, Solé F, Arenillas L, Montoro J, Valcárcel D, Pedro C, Sanzo C, Luño E, Giménez T, Arnan M, Pomares H, De Paz R, Arrizabalaga B, Jerez A, Martínez AB, Sánchez-Castro J, Rodríguez-Gambarte JD, Raya JM, Ríos E, Rodríguez-Rivera M, Espinet B, Florensa L.

PLoS One. 2015 Jun 12;10(6):e0129375. doi: 10.1371/journal.pone.0129375. eCollection 2015.

34.

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet S, Benlloch L, Sanz G; Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish Society of Hematology.

Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038/leu.2015.115. Epub 2015 May 6.

PMID:
25943181
35.

Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia.

Barba P, Martino R, Martinez-Cuadron D, Olga G, Esquirol A, Gil-Cortés C, Gonzalez J, Fernandez-Avilés F, Valcárcel D, Guardia R, Duarte RF, Hernandez-Rivas JM, Abella E, Montesinos P, Ribera JM.

Leuk Lymphoma. 2015;56(10):2812-8. doi: 10.3109/10428194.2015.1014365. Epub 2015 Mar 6.

PMID:
25686647
36.

Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.

García-Cadenas I, Castillo N, Martino R, Barba P, Esquirol A, Novelli S, Orti G, Garrido A, Saavedra S, Moreno C, Granell M, Briones J, Brunet S, Navarro F, Ruiz I, Rabella N, Valcárcel D, Sierra J.

Bone Marrow Transplant. 2015 Apr;50(4):579-84. doi: 10.1038/bmt.2014.298. Epub 2015 Jan 12.

PMID:
25581404
37.

Few and nonsevere adverse infusion events using an automated method for diluting and washing before unrelated single cord blood transplantation.

Castillo N, García-Cadenas I, García O, Barba P, Diaz-Heredia C, Martino R, Azqueta C, Ferrà C, Canals C, Elorza I, Olivé T, Badell I, Sierra J, Duarte R, Valcárcel D, Querol S.

Biol Blood Marrow Transplant. 2015 Apr;21(4):682-7. doi: 10.1016/j.bbmt.2014.12.015. Epub 2014 Dec 27.

38.

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.

Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD).

Leuk Res. 2015 Jan;39(1):52-7. doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30.

PMID:
25487012
39.

Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.

Parody R, Martino R, de la Cámara R, García-Noblejas A, Esquirol A, Garcia-Cadenas I, Villaescusa T, Caballero D, Rovira M, Fernandez-Avilés F, Marquez-Malaver FJ, Espigado I, Castilla-Llorente C, Heras I, Cabero MA, Cabrera JR, Barba P, Valcarcel D, Sánchez-Ortega I, Duarte RF, Serrano D, Carretero F, Vazquez L.

Bone Marrow Transplant. 2015 Feb;50(2):274-81. doi: 10.1038/bmt.2014.229. Epub 2014 Oct 27.

PMID:
25347007
40.

GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.

Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, Martino R, Martinez C, Solano C, Barba P, Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, Sierra J, Caballero D, Perez-Simón JA.

Bone Marrow Transplant. 2015 Jan;50(1):121-6. doi: 10.1038/bmt.2014.220. Epub 2014 Oct 13.

PMID:
25310306
41.

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Vallejo C, Batlle M, Vázquez L, Solano C, Sampol A, Duarte R, Hernández D, López J, Rovira M, Jiménez S, Valcárcel D, Belloch V, Jiménez M, Jarque I; Subcommittee of Non-Infectious Complications of the Grupo Español de Trasplante Hematopoyético (GETH).

Haematologica. 2014 Oct;99(10):1632-7. doi: 10.3324/haematol.2014.105908. Epub 2014 Jul 4.

42.

[Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].

Barba P, Fox ML, Blanco A, Valcárcel D.

Med Clin (Barc). 2015 Feb 20;144(4):184-5. doi: 10.1016/j.medcli.2014.04.006. Epub 2014 Jun 18. Spanish. No abstract available.

PMID:
24952663
43.

Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome.

Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, Lazarus HM, Laughlin MJ, Lill M, O'Brien T, Perales MA, Rocha V, Savani BN, Szwajcer D, Valcarcel D, Eapen M.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1418-25. doi: 10.1016/j.bbmt.2014.05.021. Epub 2014 Jun 2.

44.

A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.

Garcia-Manero G, Gartenberg G, Steensma DP, Schipperus MR, Breems DA, de Paz R, Valcárcel D, Kranenburg B, Reddy M, Komrokji RS.

Am J Hematol. 2014 Sep;89(9):E156-62. doi: 10.1002/ajh.23780. Epub 2014 Jun 23.

45.

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.

Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF; Spanish Group on Myelodysplastic Syndromes (GES MD).

Br J Haematol. 2014 Jul;166(2):189-201. doi: 10.1111/bjh.12876. Epub 2014 Apr 10.

PMID:
24716538
46.

Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.

García Cadenas I, Valcarcel D, Martino R, Piñana JL, Barba P, Novelli S, Esquirol A, Garrido A, Saavedra S, Granell M, Moreno C, Briones J, Brunet S, Sierra J.

Mediators Inflamm. 2014;2014:620682. doi: 10.1155/2014/620682. Epub 2014 Jan 30.

47.

[Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].

López MF, Mingot ME, Valcárcel D, Vicente García V, Perrin A, Campos Tapias I.

Med Clin (Barc). 2015 May 8;144(9):389-96. doi: 10.1016/j.medcli.2013.11.035. Epub 2014 Feb 22. Spanish.

PMID:
24565604
48.

Optimization of health-care organization and perceived improvement of patient comfort by switching from intra-venous BU four-times-daily infusions to a once-daily administration scheme in adult hematopoietic stem cell recipients.

Xhaard A, Rzepecki P, Valcarcel D, Santarone S, Fürst S, Serrano D, De Angelis G, Krüger W, Scheid C.

Bone Marrow Transplant. 2014 Apr;49(4):509-12. doi: 10.1038/bmt.2013.220. Epub 2014 Jan 13.

PMID:
24419513
49.

Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.

Barba P, Martino R, Pérez-Simón JA, Fernández-Avilés F, Castillo N, Piñana JL, López-Anglada L, Rovira M, Bosch F, Carreras E, Corral LL, Sierra J, Valcárcel D.

Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72. doi: 10.1016/j.bbmt.2013.10.011. Epub 2013 Oct 17.

50.

5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.

Ortega M, Mallo M, Solé F, Sánchez-Morata C, López-Andreoni L, Martínez-Morgado N, Gironella M, Valcárcel D, Vallespí T.

Leuk Res. 2013 Oct;37(10):1248-50. doi: 10.1016/j.leukres.2013.06.021. Epub 2013 Jul 26.

PMID:
23891188

Supplemental Content

Loading ...
Support Center